SSY Group Limited Receives Key Drug Approvals from China’s NMPA

Significant Milestones in Product Development May Impact Shareholder Value

SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) has announced a major development in its pharmaceutical product pipeline, which could have significant implications for its business prospects and potentially influence its share price.

Key Highlights

• Approval for Diltiazem Hydrochloride for Injection (10mg): The Group has received official approval for both the production and registration of Diltiazem Hydrochloride for Injection (10mg) from the National Medical Products Administration of China (NMPA). This product falls under the “type 4 chemical drug” category and has successfully passed the consistency evaluation required for such drugs.
• Therapeutic Applications: Diltiazem Hydrochloride for Injection is primarily indicated for:
  • Supraventricular tachycardia
  • Emergency management of abnormally high blood pressure during surgery
  • Hypertensive emergencies
  • Unstable angina
• Approval for Propranolol Hydrochloride Injection (5ml: 5mg and 2ml: 2mg): The Group has also secured NMPA approval for both the production and registration of Propranolol Hydrochloride Injection in two dosages (5ml: 5mg and 2ml: 2mg). This product is classified as a “type 3 chemical drug” and has also met consistency evaluation standards.
• Therapeutic Applications: Propranolol Hydrochloride Injection is used for:
  • Control of supraventricular tachyarrhythmias and ventricular arrhythmias
  • Exertional angina
  • Pheochromocytoma (used with α-blockers to control tachycardia)
  • Hypertensive emergencies
  • Unstable angina
• Propranolol Hydrochloride Bulk Drug Approval: As announced previously (on 13 February 2026), the Group’s Propranolol Hydrochloride bulk drug has already obtained registration approval from the NMPA, making it an approved bulk drug for use in market preparations.

Why This Is Important for Investors

• Regulatory Approvals: The granting of these approvals by the NMPA is a significant milestone, as it allows SSY Group Limited to manufacture and market these important cardiovascular drugs within China’s large and growing healthcare market.
• Expansion of Product Portfolio: The ability to offer both Diltiazem Hydrochloride and Propranolol Hydrochloride in injectable forms, alongside approved bulk drug capacity, strengthens the Group’s competitive position and widens its addressable market.
• Potential for Revenue Growth: These drugs are widely used for emergency and in-hospital situations, targeting conditions such as arrhythmias, hypertensive crises, and angina, which are common in the patient population. This could translate to meaningful sales growth and improved financial performance.
• Share Price Sensitivity: The successful approvals represent a de-risking event for these products and may positively influence investor sentiment and the Company’s valuation.

Board Statements and Corporate Information

The announcement was made by Chow Hing Yeung, Executive Director and Company Secretary, on behalf of the Board. As of the announcement date, the Board composition includes a mix of executive, non-executive, and independent non-executive Directors, underscoring robust corporate governance.

Conclusion

Investors should view these regulatory approvals as positive developments for SSY Group Limited. They underscore the Group’s ability to bring new, high-demand products to market and support its strategic ambitions in the pharmaceutical industry. Continued product pipeline progress and successful commercialization efforts could further enhance shareholder value.

Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any securities. Investors should conduct their own research or consult with a licensed financial advisor before making investment decisions. Share prices can be volatile and are subject to market risks.

View SSY GROUP Historical chart here